Danset 8 Mg 3 Ampoules

Danset 8 Mg 3 Ampoules

Description:

Danset 8 mg/4 ml 3 ampoules is a prescription antiemetic medicine containing ondansetron, a selective serotonin 5-HT3 receptor antagonist. It is used to prevent and treat nausea and vomiting, particularly those associated with cancer chemotherapy, radiotherapy, and postoperative recovery after surgery. Each sterile injectable ampoule is designed for intramuscular (im) or intravenous (iv) administration by healthcare professionals in hospital or clinical settings to provide rapid and reliable control of severe nausea and vomiting.

Indications:

• Prevention of acute nausea and vomiting induced by cytotoxic chemotherapy.
• Prevention of delayed nausea and vomiting associated with certain chemotherapy regimens (as part of a treatment protocol as directed by a physician).
• Prevention of nausea and vomiting associated with radiotherapy.
• Prevention and treatment of postoperative nausea and vomiting (ponv) following surgery and anesthesia.
• Management of severe nausea and vomiting where 5-HT3 receptor antagonists are indicated, as assessed by a healthcare professional.

Active Ingredients / Key Components:

• Ondansetron hydrochloride (as ondansetron) – 8 mg per 4 ml ampoule.
• Excipients: Information on inactive ingredients (such as sodium chloride, citric acid, sodium citrate, water for injection, and others) is not fully available in the provided data. Please refer to the official package insert for the complete excipient list.

Dosage & Administration / How to Use:

• Danset ampoules are for intramuscular (im) or intravenous (iv) use only and must be administered by a doctor, nurse, or qualified healthcare professional. Do not self-inject.
• Chemotherapy-induced nausea and vomiting (cinv): Typical adult dosing regimens may include 8 mg administered as a slow iv injection or short infusion immediately before chemotherapy, followed by additional doses or oral therapy as directed by the oncologist. Exact dose, timing, and duration depend on the chemotherapy regimen and patient factors and must be determined by the treating physician.
• Radiotherapy-induced nausea and vomiting: Dose and schedule are determined by the physician based on the type and intensity of radiotherapy.
• Postoperative nausea and vomiting (ponv): For prevention, ondansetron is usually given shortly before or after induction of anesthesia; for treatment, it may be given if nausea and vomiting occur postoperatively. Dose and route (im or iv) are determined by the anesthetist or surgeon.
• Use in children and elderly: Pediatric and geriatric dosing must be adjusted by the physician according to body weight, clinical condition, and current guidelines. Do not use in children without medical supervision.
• May be given with or without food since it is administered parenterally; food does not affect its absorption.
• Always follow the exact dosing schedule, infusion rate, and dilution instructions provided in the official prescribing information and by your healthcare provider.

Clinical Benefits:

• Provides effective prevention and control of chemotherapy-induced nausea and vomiting, improving patient comfort and adherence to cancer treatment.
• Reduces the incidence and severity of postoperative nausea and vomiting, supporting smoother recovery after surgery and anesthesia.
• Acts selectively on 5-HT3 receptors in the gut and brain, blocking serotonin-mediated vomiting pathways for targeted antiemetic action.
• Helps maintain hydration and nutritional intake by reducing vomiting episodes, thereby supporting overall clinical stability and quality of life during intensive treatments.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity or allergy to ondansetron or any component of the formulation, or to other selective 5-HT3 receptor antagonists.
• Use with caution in patients with a history of cardiac arrhythmias, prolonged qt interval, congestive heart failure, electrolyte disturbances (such as hypokalemia or hypomagnesemia), or those taking other medicines that prolong the qt interval. ECG monitoring may be required in high-risk patients.
• Use with caution in patients with severe hepatic impairment; dose adjustment may be necessary as ondansetron is metabolized in the liver.
• May mask progressive ileus or gastric distension; monitor patients with abdominal surgery or gastrointestinal obstruction carefully.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Ondansetron should be used in pregnancy or lactation only if clearly needed and prescribed by a physician.
• Inform your doctor about all medications you are taking, including antiarrhythmics, antidepressants, antipsychotics, antibiotics, and other medicines that may affect heart rhythm or serotonin levels (risk of serotonin syndrome when combined with certain serotonergic drugs).
• Not intended for self-medication or over-the-counter use. Use only under medical supervision.
• Keep out of reach of children.
• Not intended to diagnose, treat, cure, or prevent any disease without a doctor’s prescription and supervision.

Side Effects:

• Common side effects: Headache, flushing, constipation, or local injection site reactions (pain, redness, or irritation). These are usually mild and transient.
• Less common side effects: Dizziness, fatigue, transient changes in liver function tests, or sensations of warmth or flushing during iv administration.
• Serious side effects (seek immediate medical attention): Signs of allergic reaction such as rash, itching, swelling of the face or throat, severe dizziness, or difficulty breathing; chest pain; irregular heartbeat or palpitations; severe dizziness or fainting (possible qt prolongation or arrhythmia); severe abdominal pain or persistent vomiting.
• If any side effects become severe, persistent, or worrying, inform your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Protect from excessive heat and freezing. Keep ampoules in the original packaging until use to protect from light. Do not use if the solution is discolored, cloudy, or contains particles. Keep container tightly closed and keep out of reach of children.

Specifications:

• Form: Injectable solution in ampoules for im/iv use.
• Strength: 8 mg ondansetron per 4 ml ampoule.
• Pack size: 3 ampoules per pack.
• Route of administration: Intravenous or intramuscular injection by healthcare professionals only.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.